source
- Gilead says its oncology and inflammation portfolio has reached critical mass after series of acquisitionsGilead Sciences CEO Daniel O’Day told Fierce that the company’s push into oncology and inflammation has now reached a point of critical mass, with a pipeline that spans early research to late‑stage…
- nPhase unveils AI-driven clinical data platform to accelerate trial design and submissionnPhase, a clinical research organization, announced the launch of an end-to-end platform called nPhase.ai that uses artificial intelligence to manage clinical trial data. The platform includes a S…